Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
Overview
Choosing between Axsome Therapeutics (NASDAQ:AXSM) and Moderna (NASDAQ:MRNA) requires balancing rapid commercial expansion against the potential of a massive, multi-use technology platform during a period of industrial shift.
Axsome focuses on treating complex central nervous system conditions with a growing portfolio of approved drugs. Moderna is leveraging its mRNA technology to move beyond the pandemic, targeting various viruses and cancers. Both companies are navigating the high-risk, high-reward landscape of drug development and commercialization.
Details
Axsome Therapeutics operates as a biopharmaceutical company dedicated to central nervous system (CNS) conditions. Its current commercial lineup includes AUVELITY for depression, SUNOSI for narcolepsy, and SYMBRAVO. The company has rapidly scaled its presence, reaching nearly 925 full-time employees by early 2026. While it manages its own commercial efforts in the United States, it utilizes strategic partnerships, such as its licensing deal with Pharmanovia, to reach patients in Europe, the Middle East, and North Africa.
Source
Originally published at www.fool.com.